Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 852-859

  Bhansali, Suraj G ^a   Balu iyer, Sathy V ^a   Morris, Marilyn E ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bioavailability; Liposomes; Lymph nodes; Lymphatic transport; Pharmacokinetics; Proteins; Route of administration; Subcutaneous administration; VEGF C156S

Indexed keywords

IODINE 125; LIPOSOME; TOSYLCHLORAMIDE SODIUM; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN C156S;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD; CELL AGGREGATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STABILITY; ENCAPSULATION; ISOTOPE LABELING; LYMPH NODE; MEMBRANE FUSION; MOUSE; NONHUMAN;

EID: 84455202472     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22795     Document Type: Article

References (38)

1. Roy H, Bhardwaj S, Yla-Herttuala S. 2006. Biology of vascular endothelial growth factors. FEBS Lett 580(12):2879-2887.
2. Rockson SG. 2008. A population-based assessment of the problem of lymphatic disease. Lymphat Res Biol 6(1):1-2.
3. Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, Dakhil N, Spilman S, Goris ML, Strauss HW, Quertermous T, Alitalo K, Rockson SG. 2002. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J 16(14):1985-1987.
4. Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, Jackson DG, Yla-Herttuala S, Alitalo K. 2001. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res 88(6):623-629.
5. Yoon YS, Murayama T, Gravereaux E, Tkebuchava T, Silver M, Curry C, Wecker A, Kirchmair R, Hu CS, Kearney M, Ashare A, Jackson DG, Kubo H, Isner JM, Losordo DW. 2003. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest 111(5):717-725.
6. Lohela M, Saaristo A, Veikkola T, Alitalo K. 2003. Lymphangiogenic growth factors, receptors and therapies. Thromb Haemost 90(2):167-184.
7. Joukov V, Kumar V, Sorsa T, Arighi E, Weich H, Saksela O, Alitalo K. 1998. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem 273(12):6599-6602.
8. McLennan D, Porter C, Charman S. 2005. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today: Technol 2(1):89-96.
9. Muranishi S, Takada K, Yoshikawa H, Murakami M. 1986. Delivery systems for peptide drugs. New York and London: Plenum Press, pp 177-189.
10. Supersaxo A, Hein WR, Steffen H. 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7(2):167-169.
11. McLennan DN, Porter CJ, Edwards GA, Martin SW, Heatherington AC, Charman SA. 2005. Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep. J Pharmacol Exp Ther 313(1):345-351.
12. Porter CJ, Charman SA. 2000. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 89(3):297-310.
13. Charman SA, Segrave AM, Edwards GA, Porter CJ. 2000. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J Pharm Sci 89(2):168-177.
14. Phillips WT, Klipper R, Goins B. 2000. Novel method of greatly enhanced delivery of liposomes to lymph nodes. J Pharmacol Exp Ther 295(1):309-313.
15. Hirnle P. 1997. Liposomes for drug targeting in the lymphatic system. Hybridoma 16(1):127-132.
16. Oussoren C, Zuidema J, Crommelin DJ, Storm G. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1328(2):261-272.
17. Bailer AJ. 1988. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16(3):303-309.
18. Nedelman JR, Gibiansky E, Lau DT. 1995. Applying Bailer's method for AUC confidence intervals to sparse sampling. Pharm Res 12(1):124-128.
19. Peng A, Straubinger RM, Balu-Iyer SV. 2010. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J 12(3):473-481.
20. Bartlett GR. 1959. Phosphorus assay in column chromatography. J Biol Chem 234(3):466-468.
21. Purohit VS, Ramani K, Kashi RS, Durrani MJ, Kreiger TJ, Balasubramanian SV. 2003. Topology of factor VIII bound to phosphatidylserine-containing model membranes. Biochim Biophys Acta 1617(1-2):31-38.
22. Garg A, Balthasar JP. 2007. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34(5):687-709.
23. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407-484.
24. Xie DD, Hale V. 1996. Factors affecting the lymphatic absorption of macromolecules following extravascular administration. Pharm Res 13:S396.
25. Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X. 2010. Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. J Pharm Sci 99(2):1028-1045.
26. Van Slooten ML, Boerman O, Romoren K, Kedar E, Crommelin DJ, Storm G. 2001. Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. Biochim Biophys Acta 1530(2-3):134-145.
27. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE. 1999. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48(11):2229-2239.
28. Vuorela-Vepsalainen P, Alfthan H, Orpana A, Alitalo K, Stenman UH, Halmesmaki E. 1999. Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. Hum Reprod 14(5):1346-1351.
29. Moriya H, Maitani Y, Shimoda N, Takayama K, Nagai T. 1997. Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administrations in rats. Pharm Res 14(11):1621-1628.
30. Patel HM, Boodle KM, Vaughan-Jones R. 1984. Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes. Biochim Biophys Acta 801(1):76-86.
31. Perkins GD, Roberts J, McAuley DF, Armstrong L, Millar A, Gao F, Thickett DR. 2005. Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury. Thorax 60(2):153-158.
32. Mager DE. 2006. Target-mediated drug disposition and dynamics. Biochem Pharmacol 72(1):1-10.
33. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. 2001. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20(6):1223-1231.
34. Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF. 2002. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 72(1):20-32.
35. Grahnen A, Kastrup K, Heinrich U, Gourmelen M, Preece MA, Vaccarello MA, Guevara-Aguirre J, Rosenfeld RG, Sietnieks A. 1993. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr Suppl 82(Suppl 391):9-13; discussion 14.
36. Biesma B, Pokorny R, Kovarik JM, Duffy FA, Willemse PH, Mulder NH, de Vries EG. 1993. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer. Cancer Res 53(24):5915-5919.
37. Segrave AM, Mager DE, Charman SA, Edwards GA, Porter CJ. 2004. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther 309(3):1085-1092.
38. Kota J, Machavaram KK, McLennan DN, Edwards GA, Porter CJ, Charman SA. 2007. Lymphatic absorption of subcutaneously administered proteins: Influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab Dispos 35(12):2211-2217.